Theranica announced today that it has signed a contract to supply its Nerivio device to the U.S. Department of Veterans Affairs (VA) for use by veterans who suffer from chronic migraine headaches.

Nerivio is worn on the upper arm for 45 minutes and uses remote electrical neuromodulation to activate the brain’s native conditioned pain modulation mechanism to treat pain and associated migraine symptoms, according to Theranica. Nerivio was cited as one of TIME’s best inventions of 2019 and recently won FDA clearance for use by adolescents.

A number of studies have outlined the prevalence of migraine amongst veterans. Thirty-six percent of veterans who completed a 12-month deployment to Iraq exhibit symptoms of migraine — three times higher than the general population, according to a report by the American Migraine Foundation.

“As a U.S. Navy veteran, I feel gratified to be able to provide veterans who suffer from migraine access to Nerivio,” said Scott Szymanski, president of Theranica US, in a news release. “Veterans are one of the most at-risk populations for migraine and other headache disorders. We are committed to have Nerivio improve the quality of life of veterans receiving medical care within the VA syst­­em, as well as those that are making the transition back to civilian life.”

“The VA is a role model for putting the well-being of its members at the highest priority,” added Theranica CEO Alon Ironi. “We are also in the process of negotiating agreements with several commercial health insurance organizations. A significant amount of clinical data has solidified that Nerivio provides an effective and safe non-pharmacological alternative for treating migraine both in adults and adolescents, while also allowing patients and physicians to track the disease and understand how to best manage it through the Nerivio mobile application.”